CONNECT WITH US
HealthTech

HealthTech

Steris inks $2.1B Xodus buyout to expand consumables portfolio

MedTech Dive logo

Published on

Add as a preferred source on Google
Steris inks $2.1B Xodus buyout to expand consumables portfolio

Steris provides hospital disinfection and sterilization equipment and services. In the most recent quarter, the company reported sales of $1.5 billion, up 7% year over year. A 9% increase in healthcare consumables revenue contributed to growth.

Xodus’ portfolio “complements and expands Steris’ offering, particularly by adding consumables used in the operating room,” Steris CEO Dan Carestio said in a statement. The acquired company has demonstrated the ability to grow at double-digit rates, the CEO added.

Steris, which aims to close the deal this year, is paying $2.1 billion for Xodus and expects to primarily finance the takeover with debt. Cash tax benefits of about $300 million will cut the net purchase price to approximately $1.8 billion, Steris said. Xodus investors could receive up to $150 million more based on performance targets in 2028.

The financial terms are reasonable, Needham analysts said. The analysts forecast that the takeover will add to Steris’ earnings per share in 2027, which will increase in 2028 and 2029.

Carestio outlined Steris’ M&A strategy last month at a Morgan Stanley event. The company is mainly interested in tuck-in deals, Carestio said. Larger M&A opportunities arise from time to time, the CEO added. When that happens, Steris is “very disciplined” about the deals it strikes, he said, focusing on technology used by hospitals, caregivers, drugmakers and medtech companies.

Buying Xodus represents a step-up in Steris’ M&A activity. 4 million, to expand its portfolio of healthcare products and services. 1 million in total in the previous fiscal year.



Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.